Portal de Periódicos da CAPES

HUMAN RENAL CELL CANCER PROLIFERATION IN TISSUE CULTURE IS TONICALLY INHIBITED BY OPIOID GROWTH FACTOR

1999; Lippincott Williams & Wilkins; Volume: 162; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(05)68157-8

1527-3792

G Bisignani, Patricia J. McLaughlin, Sarah Ordille, M. SCOTT BELTZ, Mark V. Jarowenko, Ian S. Zagon,

Neuropeptides and Animal Physiology

No AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Dec 1999HUMAN RENAL CELL CANCER PROLIFERATION IN TISSUE CULTURE IS TONICALLY INHIBITED BY OPIOID GROWTH FACTOR GEOFFREY J. BISIGNANI, PATRICIA J. MCLAUGHLIN, SARAH D. ORDILLE, M. SCOTT BELTZ, MARK V. JAROWENKO, and IAN S. ZAGON GEOFFREY J. BISIGNANIGEOFFREY J. BISIGNANI More articles by this author , PATRICIA J. MCLAUGHLINPATRICIA J. MCLAUGHLIN More articles by this author , SARAH D. ORDILLESARAH D. ORDILLE More articles by this author , M. SCOTT BELTZM. SCOTT BELTZ More articles by this author , MARK V. JAROWENKOMARK V. JAROWENKO More articles by this author , and IAN S. ZAGONIAN S. ZAGON More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)68157-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Peptide growth factors alter cellular events by binding to specific receptors. One group of peptides, the endogenous opioids, is important in the growth of normal and neoplastic tissue. [Met5]enkephalin, also termed opioid growth factor (OGF), is a tonically active inhibitory factor that interacts with the OGF receptor, OGFr, formerly identified as Greek zeta (ζ) and appears to be autocrine produced by human cancer cells. This study examined the hypothesis that OGF directly inhibits proliferation of renal cell carcinoma in tissue culture. Materials and Methods: Human renal cancer cells (Caki-2) were grown using routine tissue culture techniques. A variety of natural and synthetic opioids including OGF, opioid antagonists, and opioid antibodies were added to renal cancer cell cultures to determine role of these peptides in renal cell carcinoma. The experiments were repeated in serum-free media, and with 4 other human renal cancer cell lines: Caki-2, A498, SN12C, and ACHN. Immunocytochemistry was performed to examine the presence of OGF and its receptor. Results: OGF was the most potent opioid peptide to influence human renal cell carcinoma. OGF depressed growth within 12 hours of treatment, with cell numbers subnormal by up to 48% of control levels. OGF action was receptor mediated, reversible, not cytotoxic, neutralized by antibodies to the peptide, and detected in the human renal cell carcinoma lines examined. OGF appeared to be autocrine produced and secreted, and was constitutively expressed. Both OGF and its receptor were detected in these cells. Conclusion: OGF tonically inhibits renal cancer cell proliferation in tissue culture, and may play a role in the pathogenesis and management of human renal cell cancer. References 1 : Cancer statistics, 1999. CA Cancer J. Clin.1999; 49: 8. Crossref, Medline, Google Scholar 2 : Global cancer statistics. CA Cancer J. Clin.1999; 49: 33. Crossref, Medline, Google Scholar 3 : Stratification of risk factors in renal cell carcinoma. Cancer1983; 52: 899. Crossref, Medline, Google Scholar 4 : Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin. Oncol.1995; 22: 42. Medline, Google Scholar 5 : Immunotherapy of renal cell carcinoma. CA Cancer J Clin.1993; 43: 177. Crossref, Medline, Google Scholar 6 : Renal cell carcinoma: management of advanced disease. J. Urol.1999; 161: 381. Link, Google Scholar 7 . New York: Springer-Verlag1991. Google Scholar 8 : Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J. Urol.1995; 153: 1085. Link, Google Scholar 9 : Antiprolierative effects of tyrosine kinase inhibitors (tryphoostins) on human bladder and renal carcinoma cells. J. Surg. Res.1995; 59: 675. Crossref, Medline, Google Scholar 10 : Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin. Cancer Res.1998; 4: 1331. Medline, Google Scholar 11 : Expression of transforming growth factor α and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res.1989; 49: 3407. Medline, Google Scholar 12 : Growth regulation of human renal carcinoma cells: Role of transforming factor α. Cancer Res.1992; 52: 3335. Medline, Google Scholar 13 : Analysis of growth factors in renal cell carcinoma. Biochem. Biophys. Res. Comm.1988; 153: 818. Crossref, Medline, Google Scholar 14 : The role of endogenous opioids and opioid receptors in human and animal cancers. In: . Caldwell, N. J.: CRC1991: 343. Google Scholar 15 : Opioid growth factor, [Met5]-enkephalin, and the etiology, pathogenesis, and treatment of gastrointestinal cancer. In: . Boca Raton, FL: CRC Press1999. Google Scholar 16 : Opioid growth factor ([Met5]-enkephalin) prevents the incidence and retards the growth of human colon cancer. Am. J. Physiol.1996; 271: R780. Medline, Google Scholar 17 : Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice. Cancer Lett.1997; 112: 167. Crossref, Medline, Google Scholar 18 : Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am. J. Physiol.1996; 271: R1. (Regulatory Integrative Comp. Physiol. 40). Medline, Google Scholar 19 : Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int. J. Oncol.1999; 14: 577. Medline, Google Scholar 20 : New human tumor cell lines. In: . New York: Plenum Press1975: 115. Google Scholar 21 : Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res.1986; 46: 4109. Medline, Google Scholar From the Departments of Surgery/Section of Urology and Neuroscience and Anatomy, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Scheau C, Draghici C, Ilie M, Lupu M, Solomon I, Tampa M, Georgescu S, Caruntu A, Constantin C, Neagu M and Caruntu C (2021) Neuroendocrine Factors in Melanoma PathogenesisCancers, 10.3390/cancers13092277, VOL. 13, NO. 9, (2277) Scarpa J, DiNatale R, Mano R, Silagy A, Kuo F, Irie T, McCormick P, Fischer G, Hakimi A and Mincer J (2021) Identifying Clear Cell Renal Cell Carcinoma Coexpression Networks Associated with Opioid Signaling and SurvivalCancer Research, 10.1158/0008-5472.CAN-20-1852, VOL. 81, NO. 4, (1101-1110), Online publication date: 15-Feb-2021. Aboalsoud A, El-Ghaiesh S, Abd Elmonem F, Salem M and Abdel Rahman M (2020) The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune responseInternational Immunopharmacology, 10.1016/j.intimp.2019.106068, VOL. 78, (106068), Online publication date: 1-Jan-2020. Bielecka Z, Maliszewska-Olejniczak K, Safir I, Szczylik C and Czarnecka A (2016) Three-dimensional cell culture model utilization in cancer stem cell researchBiological Reviews, 10.1111/brv.12293, VOL. 92, NO. 3, (1505-1520), Online publication date: 1-Aug-2017. Xu X, Gao Y, Wen L, Zhai Z, Zhang S, Shan F and Feng J (2016) Methionine enkephalin regulates microglia polarization and functionInternational Immunopharmacology, 10.1016/j.intimp.2016.08.037, VOL. 40, (90-97), Online publication date: 1-Nov-2016. Zhao D, Plotnikoff N, Griffin N, Song T and Shan F (2016) Methionine enkephalin, its role in immunoregulation and cancer therapyInternational Immunopharmacology, 10.1016/j.intimp.2016.02.015, VOL. 37, (59-64), Online publication date: 1-Aug-2016. Mizerska-Dudka M and Kandefer-Szerszeń M (2014) Opioids, Neutral Endopeptidase, its Inhibitors and Cancer: Is There a Relationship among them?Archivum Immunologiae et Therapiae Experimentalis, 10.1007/s00005-014-0311-0, VOL. 63, NO. 3, (197-205), Online publication date: 1-Jun-2015. Zagon I, Donahue R and McLaughlin P (2013) Targeting the opioid growth factor: Opioid growth factor receptor axis for treatment of human ovarian cancerExperimental Biology and Medicine, 10.1177/1535370213488483, VOL. 238, NO. 5, (579-587), Online publication date: 1-May-2013. McLaughlin P, Keiper C, Verderame M and Zagon I (2012) Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closureAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 10.1152/ajpregu.00670.2011, VOL. 302, NO. 9, (R1084-R1090), Online publication date: 1-May-2012. Donahue R, McLaughlin P and Zagon I (2012) Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancerExperimental Biology and Medicine, 10.1258/ebm.2011.011321, VOL. 237, NO. 2, (167-177), Online publication date: 1-Feb-2012. Donahue R, McLaughlin P and Zagon I (2011) Low-dose naltrexone targets the opioid growth factor–opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture modelExperimental Biology and Medicine, 10.1258/ebm.2011.011121, VOL. 236, NO. 9, (1036-1050), Online publication date: 1-Sep-2011. Wu J, Zhang Y, Frilot N, Kim J, Kim W and Daaka Y (2011) Prostaglandin E2 Regulates Renal Cell Carcinoma Invasion through the EP4 Receptor-Rap GTPase Signal Transduction PathwayJournal of Biological Chemistry, 10.1074/jbc.M110.187344, VOL. 286, NO. 39, (33954-33962), Online publication date: 1-Sep-2011. Donahue R, McLaughlin P and Zagon I (2011) Overexpression of OGFr Downregulates Ovarian Cancer Cell Proliferation In Vitro and Inhibits TumorigenesisJournal of Cancer Therapy, 10.4236/jct.2011.24078, VOL. 02, NO. 04, (579-594), . Donahue R, Zagon I and McLaughlin P (2011) The Opioid Growth Factor Inhibits Established Ovarian Cancer in Nude Mice and Can Be Combined with Taxol or Cisplatin to Enhance Growth InhibitionJournal of Cancer Therapy, 10.4236/jct.2011.22013, VOL. 02, NO. 02, (110-124), . Pasternak G (2011) Opioid Receptors: The Early Years The Opiate Receptors, 10.1007/978-1-60761-993-2_4, (59-91), . Avella D, Kimchi E, Donahue R, Tagaram H, McLaughlin P, Zagon I and Staveley-O'Carroll K (2010) The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancerAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 10.1152/ajpregu.00646.2009, VOL. 298, NO. 2, (R459-R466), Online publication date: 1-Feb-2010. McLaughlin P, Zagon I, Park S, Conway A, Donahue R and Goldenberg D (2009) Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axisBMC Cancer, 10.1186/1471-2407-9-369, VOL. 9, NO. 1, Online publication date: 1-Dec-2009. Zagon I, Donahue R and McLaughlin P (2009) Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancersAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 10.1152/ajpregu.00414.2009, VOL. 297, NO. 4, (R1154-R1161), Online publication date: 1-Oct-2009. Marzioni M, Invernizzi P, Candelaresi C, Maggioni M, Saccomanno S, Selmi C, Rychlicki C, Agostinelli L, Cassani B, Miozzo M, Pasini S, Fava G, Alpini G and Benedetti A (2009) Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growthDigestive and Liver Disease, 10.1016/j.dld.2008.09.011, VOL. 41, NO. 7, (523-533), Online publication date: 1-Jul-2009. Donahue R, McLaughlin P and Zagon I (2009) Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axisAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 10.1152/ajpregu.00075.2009, VOL. 296, NO. 6, (R1716-R1725), Online publication date: 1-Jun-2009. Goldenberg D, Zagon I, Fedok F, Crist H and McLaughlin P (2008) Expression of Opioid Growth Factor (OGF)–OGF Receptor (OGFr) Axis in Human Nonmedullary Thyroid CancerThyroid, 10.1089/thy.2008.0112, VOL. 18, NO. 11, (1165-1170), Online publication date: 1-Nov-2008. Zagon I, Rahn K and McLaughlin P (2007) Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cellsNeuropeptides, 10.1016/j.npep.2007.08.002, VOL. 41, NO. 6, (441-452), Online publication date: 1-Dec-2007. Horvat Š, Mlinarić-Majerski K, Glavaš-Obrovac L, Jakas A, Veljković J, Marczi S, Kragol G, Roščić M, Matković M and Milostić-Srb A (2006) Tumor-Cell-Targeted Methionine-enkephalin Analogues Containing Unnatural Amino Acids: Design, Synthesis, and in Vitro Antitumor ActivityJournal of Medicinal Chemistry, 10.1021/jm051026+, VOL. 49, NO. 11, (3136-3142), Online publication date: 1-Jun-2006. Marzioni M, Alpini G, Saccomanno S, de Minicis S, Glaser S, Francis H, Trozzi L, Venter J, Orlando F, Fava G, Candelaresi C, Macarri G and Benedetti A (2006) Endogenous Opioids Modulate the Growth of the Biliary Tree in the Course of CholestasisGastroenterology, 10.1053/j.gastro.2006.02.021, VOL. 130, NO. 6, (1831-1847), Online publication date: 1-May-2006. Zagon I, Jaglowski J, Verderame M, Smith J, Leure-duPree A and McLaughlin P (2005) Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinomaCancer Chemotherapy and Pharmacology, 10.1007/s00280-005-1028-x, VOL. 56, NO. 5, (510-520), Online publication date: 1-Nov-2005. Zagon I and McLaughlin P (2005) Opioids and differentiation in human cancer cellsNeuropeptides, 10.1016/j.npep.2005.07.001, VOL. 39, NO. 5, (495-505), Online publication date: 1-Oct-2005. Smith J, Conter R, Bingaman S, Harvey H, Mauger D, Ahmad M, Demers L, Stanley W, McLaughlin P and Zagon I (2004) Treatment of advanced pancreatic cancer with opioid growth factor: phase IAnti-Cancer Drugs, 10.1097/00001813-200403000-00003, VOL. 15, NO. 3, (203-209), Online publication date: 1-Mar-2004. Rouzaire-Dubois B, Malo M, Milandri J and Dubois J (2004) Cell size-proliferation relationship in rat glioma cellsGlia, 10.1002/glia.10320, VOL. 45, NO. 3, (249-257), Online publication date: 1-Feb-2004. Zagon I, Verderame M and McLaughlin P (2003) The expression and function of the OGF–OGFr axis – a tonically active negative regulator of growth – in COS cellsNeuropeptides, 10.1016/j.npep.2003.07.001, VOL. 37, NO. 5, (290-297), Online publication date: 1-Oct-2003. McLaughlin P, Levin R and Zagon I (2003) Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude miceCancer Letters, 10.1016/S0304-3835(03)00341-0, VOL. 199, NO. 2, (209-217), Online publication date: 1-Sep-2003. Sassani J, Zagon I and McLaughlin P (2009) Opioid growth factor modulation of corneal epithelium: Uppers and downersCurrent Eye Research, 10.1076/ceyr.26.4.249.15427, VOL. 26, NO. 5, (249-262), Online publication date: 1-Jan-2003. Zagon I, Jenkins J, Sassani J, Wylie J, Ruth T, Fry J, Lang C and McLaughlin P (2002) Naltrexone, an Opioid Antagonist, Facilitates Reepithelialization of the Cornea in Diabetic RatDiabetes, 10.2337/diabetes.51.10.3055, VOL. 51, NO. 10, (3055-3062), Online publication date: 1-Oct-2002. McLaughlin P, Wylie J, Bloom G, Griffith J and Zagon I (2002) Chronic exposure to the opioid growth factor, [Met5]-enkephalin, during pregnancy: Maternal and preweaning effectsPharmacology Biochemistry and Behavior, 10.1016/S0091-3057(01)00649-9, VOL. 71, NO. 1-2, (171-181), Online publication date: 1-Jan-2002. Zagon I, Wylie J, Hurst W and McLaughlin P (2001) Transplacental transfer of the opioid growth factor, [Met 5 ]-enkephalin, in ratsBrain Research Bulletin, 10.1016/S0361-9230(01)00518-4, VOL. 55, NO. 3, (341-346), Online publication date: 1-Jun-2001. Vaccarino A and Kastin A (2000) Endogenous opiates: 1999Peptides, 10.1016/S0196-9781(00)00345-4, VOL. 21, NO. 12, (1975-2034), Online publication date: 1-Dec-2000. Zagon I, Verderame M, Zimmer W and McLaughlin P (2000) Molecular characterization and distribution of the opioid growth factor receptor (OGFr) in mouseMolecular Brain Research, 10.1016/S0169-328X(00)00232-1, VOL. 84, NO. 1-2, (106-114), Online publication date: 1-Dec-2000. Zagon I, Verderame M, Allen S and McLaughlin P (2000) Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humansBrain Research, 10.1016/S0006-8993(99)02330-6, VOL. 856, NO. 1-2, (75-83), Online publication date: 1-Feb-2000. Volume 162Issue 6December 1999Page: 2186-2191 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.KeywordsOGFrenal cell canceropioid growth factortissue culture[Met5]-enkephalinMetricsAuthor Information GEOFFREY J. BISIGNANI More articles by this author PATRICIA J. MCLAUGHLIN More articles by this author SARAH D. ORDILLE More articles by this author M. SCOTT BELTZ More articles by this author MARK V. JAROWENKO More articles by this author IAN S. ZAGON More articles by this author Expand All Advertisement PDF downloadLoading ...